Core Insights - BioCardia, Inc. is set to present a corporate update at the H. C. Wainwright 27th Annual Global Investment Conference, highlighting recent progress and milestones in their therapeutic developments [1][4] - The presentation will focus on three clinical cell therapy programs aimed at treating ischemic heart disease, along with ongoing regulatory efforts for FDA and Japan PMDA approvals for their CardiAMP cell therapy [2][3] - BioCardia has recently formed a partnership to develop and commercialize Heart3D fusion imaging and is pursuing nondilutive funding for its CardiALLO allogeneic mesenchymal stem cell program [3] Presentation Details - Dr. Peter Altman, President and CEO of BioCardia, will present on September 10, 2025, at 2:00 PM ET at the Lotte New York Palace Hotel [2][7] - The conference will take place from September 8-10, 2025, and registered attendees can access the presentation through the conference platform [4][5] - Attendees are encouraged to request one-on-one meetings with the company through various channels [4]